Author

K. Nag

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 2 Immunology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:proteomics· 2 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1

Frequent Co-Authors

M. M. R. Khan· 4 shared M. Mohiuddin· 4 shared N. Sultana· 4 shared R. Roy· 4 shared S. Kumar· 4 shared B. K. Biswas· 3 shared H. Khan· 3 shared M. E. H. Bappi· 3 shared

Activity by Year

2020-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersBioengineering

M. M. R. Khan

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Determining the shelf life of an erythropoietin alfa biosimilar GBPD002 through stability study

K. Nag, M. Mohiuddin, S. Kumar, M. M. R. Khan, M. E. H. Sarker, B. K. Biswas, R. Roy, M. T. Molla, R. Roy, M. E. H. Bappi, A. Rahman, S. R. Haq, M. S. Sarker, P. M. Popy, R. F. Mumu, , N. Sultana

This study evaluates the stability of the erythropoietin alfa biosimilar GBPD002 under various environmental conditions and determines its shelf life as 24 months.

bioRxiv · Aug 5, 2023 · PreprintPharmacology & Toxicology

Development and qualification of a high-yield recombinant human Erythropoietin biosimilar

K. Nag, M. J. Islam, M. M. R. Khan, M. M. Rahman Chowdhury, M. E. Haq Sarker, S. Kumar, H. Khan, S. Chakraborty, R. Roy, R. Roy, M. S. K. Oli, U. Barman, M. E. H. Bappi, B. K. Biswas, M. Mohiuddin, N. Sultana

This paper develops and characterizes a high-yield biosimilar of recombinant human erythropoietin (rhEPO) that meets regulatory requirements and offers a cost-effective alternative.

bioRxiv · Jan 22, 2023 · PreprintBioengineering

A Cost-effective Purification Process for Erythropoietin Biosimilar through Downstream Process Engineering

K. Nag, M. E. H. Sarker, S. Kumar, S. Chakraborty, H. Khan, M. J. Islam, M. M. R. Khan, M. M. R. Chowdhury, R. Roy, R. Roy, B. K. Biswas, M. E. H. Bappi, M. Mohiuddin, N. Sultana

This study develops a scalable and reproducible downstream purification process for EPO biosimilar, meeting quality requirements and reducing production costs.

bioRxiv · Jan 18, 2023 · PreprintBioengineering

BANCOVID, the first D614G variant mRNA-based vaccine candidate against SARS-CoV-2 elicits neutralizing antibody and balanced cellular immune response

J. C. Baray, M. M. R. Khan, A. Mahmud, M. J. Islam, S. Myti, M. R. Ali, M. E. H. Sarker, S. Kumar, M. M. H. Chowdhury, R. Roy, F. Islam, U. Barman, H. Khan, S. Chakraborty, M. M. Hossain, , K. Nag

This paper develops and characterizes an mRNA-LNP vaccine candidate targeting the D614G variant of SARS-CoV-2, showing neutralizing antibody and balanced cellular immune responses in preclinical trials.

bioRxiv · Sep 29, 2020 · PreprintImmunology